Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.73 |
| ▸ | KDR | P35968 | 7/20 | 0.73 |
| ▸ | LCK | P06239 | 6/20 | 0.73 |
| ▸ | TEK | Q02763 | 6/20 | 0.73 |
| ▸ | EGFR | P00533 | 3/20 | 0.64 |
| ▸ | ABL1 | P00519 | 2/20 | 0.64 |
| ▸ | ABL2 | P42684 | 2/20 | 0.64 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.58 |
| ▸ | RET | P07949 | 4/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | PRKDC | P78527 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7006502 | 0.85 | LCK (0.81) | SRCKDRLCKTEKEGFR | |
| SCHEMBL3787827 | 0.85 | KDR (1.00) | SRCKDRLCKTEKEGFR | |
| SCHEMBL7012365 | 0.84 | KDR (0.64) | SRCKDRLCKTEKEGFR | |
| SCHEMBL18520776 | 0.83 | LCK (0.70) | SRCKDRLCKTEKEGFR | |
| SCHEMBL7013873 | 0.83 | KDR (0.63) | SRCKDRLCKTEKEGFR | |
| SCHEMBL7005973 | 0.82 | SRC (0.80) | SRCKDRLCKTEKEGFR | |
| SCHEMBL7004833 | 0.82 | KDR (0.62) | SRCKDRLCKTEKEGFR | |
| SCHEMBL7007563 | 0.82 | KDR (0.62) | SRCKDRLCKTEKEGFR | |
| SCHEMBL7005163 | 0.81 | SRC (0.81) | SRCKDRLCKTEKEGFR | |
| SCHEMBL7007578 | 0.80 | KDR (0.59) | SRCKDRLCKTEKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | SRC 1332/4885KDR 4598/4885LCK 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.